Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

uch patients are characterized by presence of chromosomal abnormalities (i.e., deletions of chromosome 17p or 11q) or short remissions (less than 3 years) after standard chemo-immunotherapy. To develop an alternative therapy regimen for this patient population, researchers explored the combination of ibrutinib and the anti-CD20 antibody rituximab in high-risk CLL.

In this Phase II study conducted at The University of Texas MD Anderson Cancer Center in Houston, ibrutinib was given in combination with rituximab to evaluate its potential to accelerate and improve CLL patient responses. Forty patients were treated with 420 mg of ibrutinib daily in combination with weekly rituximab for four weeks, followed by ibrutinib daily plus monthly rituximab until month six, followed by single-agent ibrutinib.

Positive responses to therapy were shown among the vast majority of treated patients. At four months of follow-up, the overall response rate was 85 percent and almost all (38 of 40) patients continued on therapy without disease progression. Of the 20 patients evaluable for early response, 17 achieved a partial remission. Patient health questionnaires also noted improvements in health and the quality of life of all treated patients.

Overall, the regimen was well-tolerated among participants, with little severe toxicity that was largely unrelated and short in duration. After treatment with ibrutinib-rituximab (iR) combination therapy, most cases of early lymphocytosis (increase in white blood cells that is a sign of infection), due to the ibrutinib-induced shift of CLL cells from lymph node tissues into the blood, peaked early and resolved; at four months of follow-up, only three treated patients had lymphocytosis that had not yet resolved. This shorter lymphocytosis duration, when compared to single-agent use of ibrutinib, is presumably related to the addition of rituximab.

"We know that high-risk CLL patients struggle with the effects of
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... 19, 2015 For some people, tattoos are ... for the rest of their lives, as they have spent ... put in a great amount of thought on their designs. ... have outgrown them or simply want them removed for personal ... their tattoo, and in 2012-13 there was a 43 percent ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post explaining ... Spring. , Spring can be a great season ... sure they compare the newest policies before deciding on ... about Spring car insurance offers by reading the newly ... becoming more and more popular. Many insurance brokerage websites ...
(Date:4/18/2015)... NEW YORK (PRWEB) April 18, 2015 ... (AMO) are hosting a ‘Strategies for Success’ program for ... Refractive Surgeons meeting in San Diego, where eye surgeon ... Moderator’ for this invitation-only event. Dr. Martin is the ... and Review of Ophthalmology chose Dr. Martin to lead ...
(Date:4/18/2015)... 2015 Patients who undergo radiation for ... later in life, but the disease is likely to ... unrelated to radiation. Surviving Mesothelioma has just posted the ... Click here to read it now. , Scientists ... of 45 patients who had both a hematologic cancer ...
(Date:4/18/2015)... April 18, 2015 On April 14th, 2015, ... Report , which they say, “exposes a tactical shift by ... malware variants were introduced in 2014 - almost a million ... Day threats to be identified and patched by prominent manufacturers ... clear that doing business in a digital world can be ...
Breaking Medicine News(10 mins):Health News:Dennis Dass, M.D. is Shattering the Past While Revealing the Future 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... 22 percent as a result of My Health ... Benefits Institute (IBI) and the National Business Coalition ... with the 2009 IBI/NBCH Healthy Workforce Productivity Award ... February 9-11 in Los Angeles. The award, sponsored ...
... Director of the Division of Gynecologic Oncology and Ira ... the Washington University School of Medicine in ... of the Society of Gynecologic Oncologists (SGO) at the ... San Antonio, Texas. Dr. Mutch received a Bachelor of ...
... Ga. A genetic risk factor that increases the likelihood ... by high levels of involved and supportive parenting, according to ... in the February issue of the Journal of Consulting ... group of youth over time to see how a genetic ...
... announced today the results from an ongoing Phase I/II ... Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal. ... for the treatment of HIV infection. During the ... a controlled scheduled treatment interruption (STI) from their current ...
... Primary Wave Media, one of the nations leading ... creation of its new 1-800-HOSPICE marketing program. ... has become very competitive and these companies are ... marketing package provides individual hospices with exclusive use ...
... Yields Results in Heart Care for MinoritiesPRINCETON, N.J., Feb. ... of National Heart Failure Week, the New Jersey Hospital ... is rapidly approaching its goal of reducing heart failure ... Americans have higher death rates than whites for both ...
Cached Medicine News:Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 2Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 3Health News:David G. Mutch Elected 41st President of the Society of Gynecologic Oncologists 2Health News:David G. Mutch Elected 41st President of the Society of Gynecologic Oncologists 3Health News:Study: Genetic risk for substance use can be neutralized by good parenting 2Health News:Penn Medicine presents HIV gene therapy trial data at CROI 2009 2Health News:Primary Wave Media Launches 1-800-HOSPICE 2Health News:NJHA Marks National Heart Failure Week 2Health News:NJHA Marks National Heart Failure Week 3
(Date:4/17/2015)... 2015   IBA Molecular, a global leader ... that it has signed a definitive agreement to sell ... NA), to Illinois Health and Science (IHS). Under IHS ownership, ... company headquartered in Dulles, Virginia , ... new product and footprint synergies. IBA Molecular is jointly ...
(Date:4/17/2015)... , April 17, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of cancer ... the presentation of data from three of its most ... Cancer Research (AACR) 106 th Annual Meeting being ... PA USA. The presentation ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 A drug ... the eyesight of people with multiple sclerosis (MS), according to ... American Academy of Neurology,s 67th Annual Meeting in ... "About half of people with MS experience at ... neuritis, in which the nerve carrying vision from the eye ...
Breaking Medicine Technology:Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Epilepsy Drug May Preserve Eyesight for People with MS 2
... Cephalon, Inc. (Nasdaq: CEPH ) today reported 2010 ... to net sales of $2.152 billion for 2009.  Basic income ... expense and certain other items, adjusted net income for full ... the previous year.  This exceeded the company,s adjusted net income ...
... are reporting problems receiving medically required home medical equipment ... Medicare,s "competitive" bidding program in Cleveland and Cincinnati. The ... and people living with disabilities in Cleveland and Cincinnati ... program began in nine areas on January 1 and ...
Cached Medicine Technology:Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 2Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 3Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 4Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 5Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 6Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 8Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 9Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 10Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 11Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 12Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 13Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 14Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 15Seniors in Ohio Report Problems With Access to Home Medical Equipment and Services Under Controversial Medicare Bidding System 2Seniors in Ohio Report Problems With Access to Home Medical Equipment and Services Under Controversial Medicare Bidding System 3
... cost walker features a non-skid rocker outsole ... profile design minimizes leg length discrepancy. Three ... strapping quick and easy. Steel uprights are ... ankle and bulky bandaging. Designed for easy ...
... low cost walker features a non-skid rocker ... low profile design minimizes leg length discrepancies. ... makes strapping quick and easy. Steel uprights ... swollen ankles and extra bandaging. This extra ...
... The High Tide walker provides comfortable ... injuries of the lower leg, stress fractures ... stable fractures of the ankle. Extension pads ... larger patients.The shorter Low Tide walker with ...
Fracture walker designed to provide maximum comfort, protection and stability...
Medicine Products: